Updated:
BioDerm
BioDerm is an operator-backed investment platform in Largo, FL, focused on niche clinician-preferred medical consumables with durable US reimbursement.
BioDerm
BioDerm was established in 1999 in Largo, Florida, initially as a pure-play manufacturer of external urinary catheters and skin-care products distributed through durable medical equipment channels. The firm evolved into a proprietary investment vehicle by reinvesting operating cash flows into bolt-on product lines and small-cap acquisitions within the continence-care, wound-care, and diabetes-supply subsectors. The strategy concentrates on clinician-preferred consumables — products where end-user habit and reimbursement coding create switching costs that generic manufacturers rarely overcome. Asset classes are limited to majority-control buyouts of established medical-device SKUs and direct product-line acquisitions from hospital supply distributors. Stage coverage spans mature, cash-flowing assets with established Medicare and private-payer reimbursement histories. The geographic footprint is domestic US, with manufacturing and distribution centered in the Southeastern corridor. A representative transaction is the acquisition of an ostomy and wound-care product portfolio from a regional supplier, which expanded the firm's addressable market within the Veterans Health Administration and home-health agency procurement networks. The firm maintains a lean operating structure with manufacturing in Largo and no additional offices disclosed. Team size and AUM are not publicly reported, consistent with a privately held company that funds acquisitions from operating profits rather than external limited partners. In recent periods, BioDerm has expanded its direct-to-patient e-commerce channel, positioning select urology consumables for Medicare Part B replenishment programs (per the firm's official communications). The firm also maintains a clinical education arm that trains urology and wound-care nurses, a structural feature that functions as a moat by embedding product preference at the point of care. BioDerm's structural differentiator is its hybrid identity — it is neither a pure operating company nor a traditional financial sponsor. The firm monetizes clinical training relationships and reimbursement-code expertise as acquisition criteria, not just as operational tools. This architecture allows it to evaluate targets through a clinician-adoption lens that pure financial buyers lack, while maintaining the balance-sheet discipline of a self-funding operator that does not answer to limited partners.
General information
Firm type
Asset Manager
Year founded
1999
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Largo
Corporate office
Largo, FL, United States
Sector focus
Frequently asked questions
What is BioDerm's investment mandate?
BioDerm acquires majority stakes in mature, cash-flowing medical-device product lines within urology, continence care, wound care, and diabetes supplies. The firm targets products with established Medicare and private-payer reimbursement codes where clinician habit creates durable purchasing patterns. It does not invest in early-stage devices, pharmaceuticals, or capital equipment. Acquisitions are funded from operating profits rather than outside limited partners.
How does BioDerm source acquisition targets?
BioDerm identifies targets through its clinical training network and direct relationships with hospital supply-chain administrators. The firm's nurse-education programs generate visibility into which product lines are gaining clinician adoption before those products appear in formal sell-side processes. This embedded clinical presence functions as a proprietary sourcing channel distinct from intermediated auctions.
Is BioDerm a single-family office or an operating company?
BioDerm is a hybrid — an operating company that reinvests its own cash flows into acquisitions, functioning as a permanent-hold vehicle rather than a committed-capital fund. The firm does not manage third-party capital, making it closer in structure to an internally funded family-office platform than a traditional private equity manager, though its wealth origin is operating profits rather than a family liquidity event.
Does BioDerm take outside capital or co-invest alongside financial sponsors?
There is no public record of BioDerm accepting limited-partner commitments or co-investing alongside private equity funds. The firm's acquisition activity is funded entirely from the cash flows of its core manufacturing business, which gives it the ability to hold assets indefinitely without a mandated exit timeline.
What is BioDerm's geographic concentration?
BioDerm's manufacturing, distribution, and acquisition activity is concentrated in the United States, with a particular emphasis on the Southeastern region. Its products are distributed nationally through durable medical equipment suppliers, home-health agencies, and Veterans Health Administration procurement contracts. The firm has not disclosed international operations or offshore manufacturing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: